This summer has been arguably the quietest and least volatile for the U.S. markets, but that hasn’t kept investors from making money. Ask the fund managers who study precious metals and emerging markets, they are sure to agree.
During the fourteen-week period between the Memorial Day and the Labor Day, better known as the “sell in May and go away” period, mutual funds from the aforementioned categories returned around 20% this year. Such a staggeringly high return was possible mostly due to low interest rates, which benefits such asset classes. Emerging markets have also seen dramatic GDP growth this year, while fears of an economic downturn in China have ebbed.
Weak global economic scenario coupled with Brexit induced volatility compelled the Fed to keep rates low in the short term. Add to this, weak service sector growth, contraction in manufacturing activity and slowdown in pace of hiring in August, and we all know that the Fed may not hike rates any time soon.
- [By Ben Levisohn]
Shares of Terex (TEX) had surged 32% as of the close of trading last Thursday–but dropped 14% the next day after China’s Zoomlion announced that it wouldn’t be pursuing a purchase of the U.S. crane maker after all. In the aftermath of the scuttled deal, Morgan Stanley’s Mili Pothiwala and Nigel Coe cut Terex to Equal Weight from Overweight:
Balint Porneczi/Bloomberg News
On Friday morning, Zoomlion announced it had terminated its bid for its proposed acquisition of Terex for $31/ share. This was a clear negative for Terex shares, which traded down ~15% on Friday to $20, given the absence of an event-driven catalyst (following the sale of MHPS to Konecranes, which we assume will be completed). However, we think that the stock’s current discount to the Machinery group on a P/E basis (20%+) is justified, given a still challenged underlying operating environment for the RemainCo, as well as historically uneven company execution – both of which return to the forefront of the investment debate following the removal of the M&A bull case.
To which all we can say is: Oops.
Shares of Terex have dropped 0.5% to $20.78
- [By Ben Levisohn]
Third and a trigger for the change: China becomes an active bidder in the space. Chinas Zoomlion bid for Terex (TEX) ($3.3B) along with Haier/General Electric (GE) ($5.4B) and several ChemChina proposed deals in industrials changes the upside/downside skew, particularly on lower quality/more challenged names. The Terex bid does not appear to be one-off. Chinese outbound M&A announcements rose to record highs in 15; to $112B (up 57% from 2014) in total acquisitions. Industrials formed a large and rising portion, at ~12B completed. Thats roughly equal to the 3 prior years industrials deals combined, and is the highest on record. Energy and materials accounted for ~15% of 15 spend vs. ~83% in 2011. Even lower quality or more currently challenged machinery franchises have distribution which could be highly attractive to new entrants…
- [By Ben Levisohn]
RBC’sSeth Weber and team offer their thoughts on Zoomlion’s revised bid for Terex (TEX):
After the close today, Terex announced that it is moving forward in its negotiations with Zoomlion Heavy Industry Science and Technology Co. following receipt of a non-binding proposal from the Chinese company to acquire all outstanding shares for $31/share in cash.
- [By Ben Levisohn]
Yesterday, Terex (TEX) announced that it would sell its ports business to Konecranes for $1.3 billion. Today, Baird’s Mircea Dobre and Joseph Grabowski upgraded Terex to Outperform from Neutral, arguing that the sale makes a takeover by China’s Zoomlion that much easier. They explain:
Balint Porneczi/Bloomberg News
The sale of MHPS to Konecranes is a positive catalyst on multiple fronts: shareholders got an attractive multiple for what historically has been a challenged business with further upside possible given 25% equity ownership in Konecranes, execution risk is diminished as new CEO can focus on operational improvement without the effort required to integrate the Terex and Konecranes businesses, and finally, the MHPS sale makes it easier for Zoomlion to acquire remaining Terex.
While our upgrade is not reliant on Zoomlion acquiring Terex, the MHPS transaction could make a firm Zoomlion offer more likely.
At the margin, a Zoomlion deal appears easier to get done: 1) the remaining businesses fit better with Zoomlions existing product portfolio of construction equipment, cranes, and various commercial and municipal equipment, 2) given the attractive terms of the MHPS sale, the funding hurdle required to acquire Terex is lowered, 3) many of the CFIUS issues center around national security concerns regarding the nations ports, no longer a concern given MHPS sale.
Dobre and Grabowski also raised their price target on Terex to $30, up from $24. With Terex off 0.1% at $24.88 today, that leaves 21% upside in the stock to Baird’s target.
In February, I wrote about Chinese demand for U.S. companies, including Terex.
- [By Reuben Gregg Brewer]
Ever walk past a construction site? It’s hard not to be enthralled by all the heavy construction machinery moving things around. With the world’s developing economies still building at a relatively fast pace and developing economies, like the United States, in desperate need of upgrading their aging infrastructure, the companies behind that construction machinery could be just as exciting as a construction site in the years ahead. Which is why Caterpillar Inc. (NYSE:CAT), Cummins Inc. (NYSE:CMI), and Terex Corporation (NYSE:TEX) are three of the top construction machinery stocks to look at right now.
- [By Bryan Murphy]
At first glance, it looks like it could be trouble for Lexaria Bioscience Corp (OTCMKTS:LXRP). That is, on Wednesday, the nation’s Drug Enforcement Agency brought clarity to a rule that had been up in the air since 2011. That is, in short, the DEA’s position on all cannabis extracts, including CBD oil, is that they are all federally illegal Schedule I substances.
From a legal and logical standpoint based just on the DEA’s language published in the Federal Register yesterday, that puts Lexaria Bioscience in jeopardy. Lexaria has developed a way to improve the body’s absorption of hemp oil — which is deliberately high in cannabidiol/CBD — which was perfectly legal and legitimate since THC percentage in hemp (0.3%or less) are technically legal. Now the federal government’s drug-enforcement arm says that’s not the case. The newly-clarified law defines the illegal substance as “extracts that have been derived from any plant of the genus Cannabis and which contain cannabinols and cannabidiols.” Hemp, even though it’s not marijuana, is of the Cannabis genus.
Bad news for LXRP owners? Not quite, for a handful of reasons.
The decision (which bypassed legislature and overstepped the DEA’s authority, by the way – more on that in a second) is evidence of a long-standing problem the government agency has had in dealing with hemp and cannabis. In simplest terms, the DEA has operated and acted as if it has no real understanding of the difference between hemp and marijuana. They are of the same genus, but not of the same species. Moreover, while the former predominantly contains cannabidiol, the latter is sought out for its high tetrahydrocannabinol (or THC) for the purpose of creating a “high.”
Problem (for the DEA): The U.S. judicial system has already ruled that the DEA doesn’t have the authority to make such rules.
Attorney Robert Hoban explained yesterday evening at industry website newcannabisventures.com:
- [By Matthew Briar]
Last week — to the day, in fact — Lexaria Bioscience Corp (OTCMKTS:LXRP) announced it was teaming up with neutraceutical company NeutriSci International Inc (CVE:NU) to create a new kind of health supplement that gave consumers the ability to tap into the benefits of hemp. We hailed it as the shape of things to come. What we didn’t know, however, was how quickly those things would take shape. Just this morning the company told LXRP shareholders it was already forging another such symbiotic relationship…. this one with Hempco Food and Fiber Inc (CVE:HEMP).
Simply put, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.
It’s not widely recognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.
Lexaria Bioscience changes this. In short, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity. Hemp, and hemp oil to be exact, can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.
The future for Lexaria Bioscience is partnerships… licensing its science and know-how to companies with existing product lines and distribution networks that can easily inject hemp
- [By Bryan Murphy]
Though they’re not the same thing, anything that’s good for marijuana is good for hemp. That’s why when eight out of nine states that had marijuana on the ballot two Tuesday’s ago approved those measures, things got a lot more compelling for owner of Lexaria Bioscience Corp (OTCMKTS:LXRP).
What’s the difference? Hemp a strains of Cannabis sativa that have been bred specifically for fiber used for clothing, construction, oils and topical ointments, nutritional benefits and a wide array of other purposes that don’t involve getting “high.” Marijuana is a slang term used to describe strains of Cannabis sativa that are bred for the potent resinous glands, or trichomes, that grow on the flowers and some leaves… the strain packed with tetrahydrocannabinol (or THC).
They would be easy to confuse, and commonly are. The potential for confusion, in fact, is the chief reason government agencies have been hesitant to support one and ban the other. With marijuana now legalized for use for one reason or another in more than half the United States though, knowledge and understanding of the difference will soon follow.
Great, but what’s that got to do with Lexaria Bioscience is on the leading edge of the movement of heightened understanding of what hemp is, and what it does.
The medical benefits of the non-psychoactive form of Cannabis sativa are impressive to say the least. Among other benefits, hempseed oil has also shown a positive effect on dermatological diseases and lipid metabolism (the process by which fatty acids are broken down in the body). Hempseed also has high levels of vitamins A, C and E and ?-carotene, and it is rich in minerals like phosphorus, potassium, magnesium, sulfur and calcium. As a food, hempseed oil is nutritious – it contains an excellent balance of polyunsaturated fatty acids – and it reportedly tastes good, too.
Problem: Hemp isn’t effectively absorbed into the body, and as such, it’s difficult to make effec
- [By Matthew Briar]
Earlier this month, some light was shed on the so-called marijuana ‘zombie’ outbreak in Brooklyn (and a handful of other places) earlier this year. As it turns out, it wasn’t a zombie outbreak at all… not that anyone really suspected the undead were lurking about. The culprit was drugs, or more specifically, chemicals and compounds that serve as drugs that weren’t meant to be utilized in that manner. In the search for a stronger, more intense high, marijuana fans got far more than they bargained for, and not in good way.
The matter inadvertently puts an up-and-coming company called Lexaria Bioscience Corp (OTCMKTS:LXRP) in the spotlight. See, Lexaria Bioscience could have sidestepped the zombie-like response of what’s now clearly been deemed a chemical-laced plant nobody would ever actually choose to smoke if they knew better. How so? Because LXRP could have provided the more intense ‘high’ being sought using its infusion science and real marijuana… not the synthetic marijuana that’s been causing unexpected results like hallucinations, extreme agitation, a rapid heartbeat and extremely high blood pressure. paranoia, anxiety, panic attacks and psychotic episodes. Those aren’t the usual responses to weed. They’re common responses to other, harsher narcotics, and are often wished avoided by recreational marijuana users.
Say what you want about the moral hazards or dangers of legalized marijuana, but nobody can deny that it’s happening… in the United States, and abroad. In November, marijuana was on the ballot for one reason or another in nine states, and the pro-marijuana movement got the green light in eight of them. Weed is now legal, either for medicinal or recreational use, in more than half the states that make up the U.S.A.
More relevant to the matter at hand, in step with the ongoing legalization of marijuana, users and sellers have — as they always do– pushed the limits of legality and science to come up with a better expe
- [By Matthew Briar]
What do you get when you cross a science that drastically improves the absorption of cannabidiol (the healthy component of cannabis) with pterostilbene (an antioxidant) tablet? It’s not a joke in search of a punch line. It’s going to be the health supplement millions of consumers have been waiting for, brought to them by a joint venture between NeutriSci International Inc (CVE:NU) and Lexaria Bioscience Corp (OTCMKTS:LXRP). The two companies announced this morning they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line.
Lexaria has developed and patented a technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.
Just to be clear, hemp and marijuana are not the same thing. Hemp doesn’t have any tetrahydrocannabinol (or THC) in it, which is the key driver of its psychoactive — the ‘high’ — response. Hemp, and hemp oil to be exact, does have cannabidiol in it though, and for those who’ve been following the saga of medical marijuana and cannabis, they’ll know cannabidiol can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.
NeutriSci International is Canadian corporation that specializes in the marketing, development and distribution of proprietary nutraceuticals. It’s got a rather wide array of products in its portfolio, but the one of immediate interest is its pterostilbene, as it fits best with the hemp-absorption technology Lexaria Bioscience brings to the table.
Pterostilbene (found in blueberries, by the way) is o
- [By Jim Robertson]
Last week, small cap food sciences stockLexaria Bioscience Corp (OTCQB: LXRP)announced a deal with Hempco Food and Fiber (OTCMKTS: HMPPF; TSXV: HEMP) that will take hemp foods to the next level. First of all, hemp is a variety of the Cannabis sativa plant species that is grown for the industrial uses of its derived products as the plant material can be refined into justabout anything,including paper, textiles, clothing, biodegradable plastics, paint, insulation, biofuel, food and animal feed: